High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation

J Thorac Cardiovasc Surg. 2008 Mar;135(3):685-7. doi: 10.1016/j.jtcvs.2007.09.018.
No abstract available

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Aprotinin / administration & dosage*
  • Blood Loss, Surgical / prevention & control*
  • Coronary Artery Bypass / methods*
  • Coronary Disease / diagnosis
  • Coronary Disease / mortality
  • Coronary Disease / surgery*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hirudins / administration & dosage*
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / administration & dosage*
  • Probability
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • Reference Values
  • Risk Assessment
  • Single-Blind Method
  • Survival Analysis
  • Treatment Outcome

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Aprotinin
  • bivalirudin